...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oral oncology >Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases
【24h】

Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases

机译：富血小板疗法治疗静脉内双膦酸酯相关性颌骨坏死：32例报道

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an important complication in cancer patients taking intravenous BPs (BPs). In most cases, BRONJ is associated with an oral surgery procedure involving jaw bone. Currently, BRONJ management remains controversial, and there is no definitive standard of care for this disease. In fact, several articles in the recent literature discuss treatments that range from topical to surgical treatment, without definitive conclusion about treatment. A clinical study was conducted on 32 patients treated with i.v BPs for oncologic pathologies affected by BRONJ. The patients were treated by resection of the necrotic bone with primary closure of the mucosa over the bony defect using plasma rich in growth factors (PRGF). Orthopanoramic and computed tomography were performed before and after surgery. No intraoperative complications were observed, and all 32 cases were treated successfully. Our data on the use of PRGF demonstrate positive results for this surgical treatment. PRGF may enhance vascularization and regeneration of osseous and epithelial tissues.
机译：双膦酸盐相关的颌骨骨坏死（BRONJ）是接受静脉内BP（BP）的癌症患者的重要并发症。在大多数情况下，BRONJ与涉及颌骨的口腔外科手术相关。目前，BRONJ的治疗仍存在争议，目前尚无明确的治疗标准。实际上，最近的文献中有几篇文章讨论了从局部治疗到手术治疗的各种治疗方法，但没有明确的治疗结论。对32例接受i.v BP治疗的患者进行了一项临床研究，研究了其受BRONJ影响的肿瘤病理。通过使用富含生长因子（PRGF）的血浆切除坏死骨并在骨缺损处进行粘膜的初次闭合来治疗患者。手术前后进行正全景和计算机断层扫描。未观察到术中并发症，所有32例均获成功治疗。我们使用PRGF的数据证明了该手术治疗的积极结果。 PRGF可能会增强骨和上皮组织的血管生成和再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号